All
Weeks of TIL Therapy ‘Buys Years’ to Next Melanoma Treatment, Expert Says
February 22nd 2024Treatment with Amtagvi, a TIL therapy recently approved for advanced melanoma, includes a three-week hospital stay upfront, but may lead to years of monitoring without more treatment needed, an expert explained.
FDA Approves Dosing Reduction of Tecvayli in Relapsed, Refractory Myeloma
February 21st 2024The Food and Drug Administration has approved a reduced dosing frequency of Tecvayli for patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for at least six months.
Tagrisso Plus Chemo Approved by FDA for EGFR-Mutated NSCLC
February 16th 2024The Food and Drug Administration has approved Tagrisso plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.